Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression

被引：8

作者：

Dubois, L.

Dresselaers, T.

Landuyt, W.

Paesmans, K.

Mengesha, A.

Wouters, B. G.

Van Hecke, P.

Theys, J.

Lambin, P.

机构：

[1] Univ Maastricht, GROW Res Inst, Dept Radiat Oncol, Maastro Lab, NL-6200 MD Maastricht, Netherlands

[2] Katholieke Univ Leuven, Biomed NMR Unit, B-3000 Louvain, Belgium

[3] Katholieke Univ Leuven, Lab Expt OncolRadiobiol, B-3000 Louvain, Belgium

来源：

BRITISH JOURNAL OF CANCER | 2007年 / 96卷 / 05期

关键词：

F-19-MRS; Salmonella typhimurium; gene therapy; cytosine deaminase; xenograft human tumour;

D O I：

10.1038/sj.bjc.6603624

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The potential utility of tumour-selective 5-fluorouracil treatment using attenuated Salmonella serovar typhimurium recombinant for cytosine deaminase (TAPET-CD) has been documented in experimental settings. The present data demonstrate that in vivo F-19-magnetic resonance spectroscopy measurements allow the outcome prediction of this prokaryotic-based therapy, demonstrating the necessity of non-invasive real-time imaging techniques for treatment monitoring.

引用

收藏

页码：758 / 761

页数：4

相关论文

共 13 条

[1] Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours [J].

Dresselaers, T ;

Theys, J ;

Nuyts, S ;

Wouters, B ;

de Bruijn, E ;

Anné, J ;

Lambin, P ;

Van Hecke, P ;

Landuyt, W .

BRITISH JOURNAL OF CANCER, 2003, 89 (09) :1796-1801

[2] Evaluation of hypoxia in an experimental rat tumour model by [18F]Fluoromisonidazole PET and immunohistochemistry [J].

Dubois, L ;

Landuyt, W ;

Haustermans, K ;

Dupont, P ;

Bormans, G ;

Vermaelen, P ;

Flamen, P ;

Verbeken, E ;

Mortelmans, L .

BRITISH JOURNAL OF CANCER, 2004, 91 (11) :1947-1954

[3]

Kamm YJL, 1996, MAGNET RESON MED, V36, P445

[4] Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent [J].

King, I ;

Bermudes, D ;

Lin, S ;

Belcourt, M ;

Pike, J ;

Troy, K ;

Le, T ;

Ittensohn, M ;

Mao, J ;

Lang, WS ;

Runyan, JD ;

Luo, X ;

Li, ZJ ;

Zheng, LM .

HUMAN GENE THERAPY, 2002, 13 (10) :1225-1233

[5] Fluorine-19 or phosphorus-31 NMR spectroscopy: A suitable analytical technique for quantitative in vitro metabolic studies of fluorinated or phosphorylated drugs [J].

Martino, R ;

Gilard, V ;

Desmoulin, F ;

Malet-Martino, M .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 38 (05) :871-891

[6]

Mei SP, 2002, ANTICANCER RES, V22, P3261

[7]

MINTON NP, 1995, FEMS MICROBIOL REV, V17, P357, DOI 10.1016/0168-6445(95)00009-2

[8] Pilot trial of genetically modified, attenuated Salmonella expressing the E-coli cytosine deaminase gene in refractory cancer patients [J].

Nemunaitis, J ;

Cunningham, C ;

Senzer, N ;

Kuhn, J ;

Cramm, J ;

Litz, C ;

Cavagnolo, R ;

Cahill, A ;

Clairmont, C ;

Sznol, M .

CANCER GENE THERAPY, 2003, 10 (10) :737-744

[9]

Schlemmer HP, 1999, CANCER RES, V59, P2363

[10] Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum [J].

Theys, J ;

Landuyt, W ;

Nuyts, S ;

Van Mellaert, L ;

van Oosterom, A ;

Lambin, P ;

Anné, J .

CANCER GENE THERAPY, 2001, 8 (04) :294-297